Translational Regenerative Medicine: Market Prospects 2014-2024

NEW YORK, Jan. 6, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Translational Regenerative Medicine: Market Prospects 2014-2024
http://www.reportlinker.com/p0595030/Translational-Regenerative-Medicine-Market-Prospects-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

Report Details

Our new study shows you the commercial potential of regenerative treatments

What does the future hold for regenerative medicine? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our study lets you assess regenerative medicine: cell-based therapies that aim to restore function and regenerate diseased tissues. It lets you assess projected sales at world market, market segment, product and regional level to 2024. You will see financial results, interviews, trends, opportunities, and revenue predictions.

In our investigation you also see qualitative analyses, news R&D and business developments. Our 240 page report provides 122 tables, charts, and graphs. Read the full transcripts of three exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Dr. Alan Trounson - President, California Institute for Regenerative Medicine (CIRM)
- Professor Francois Berthiaume - Associate Professor of Biomedical Engineering, Rutgers University, New Jersey
- Dr. William Dolphin - CEO, Avita Medical

You will find prospects for submarkets and products

In addition to analyses of the overall world market, you will see revenue forecasting of three world-level submarkets to 2024:
• Stem cell therapy
• Tissue engineered products
• Gene therapy

Also, you will discover how leading products - including Apligraf, Dermagraft, ReCell, Osteocel Plus, Trinity Evolution and Neovasculgen - perform from 2014 to 2024. You will find business research and analysis with individual revenue forecasts and discussions.

What are the prospects in leading regions and countries?

There are many commercial opportunities in developed and developing countries. You discover individual revenue forecasts to 2024 for regions, with discussions of countries:
• US
• Europe
• Asia Pacific - including Japan, China, India, South Korea and Australia
• Rest of the world - including Brazil

This decade, revenues from the Asia-Pacific region will be the fastest-growing worldwide.
Revenues in many countries will multiply many times from 2014 to 2024, our analyses show.

Research and development - potential in this emerging industry

What's happening in the R&D pipeline for translational regenerative medicine? Our study shows developmental trends:
• Diabetes treatments
• Cardiovascular and cardiology treatments
• Cancer therapy
• Ocular (ophthalmological) uses - treating eye diseases
• Wound care
• Treatments for neurological disorders

Discover how science and technology is changing translational regenerative medicine. Our investigation shows you trends and outlooks, exploring matters affecting the sector.

What issues affect the regenerative treatments and industry market?

Our study lets you assess industry trends and outlooks. You will find discussions, including qualitative analyses:
• Tissue engineering - including 3D bioprinting and organ transplants
• Autologous chondrocyte implantation (ACI)
• Haematopoietic stem cell transplantation and other cellular treatments
• Orthobiologics, biomaterials, neuroprotection and nanotechnology
• Gene therapy, including delivery and viral vectors
• Bone marrow material and human embryonic stem cells
• Mesenchymal stem cell technologies
• Skin regeneration, wound repair, cosmetic uses and treating degenerative disorders
• Treatment of leg ulcers, cartilage, livers, hearts and eyes

You will see discussions of technological, commercial, and economic matters, with emphasis on organisations developing technologies.

Leading companies and potential for market growth

This decade, this biotechnology sector will flourish - already there are products on sale and a myriad of clinical trials underway.

The R&D pipeline is strong and promising. Visiongain expects high demand for treatments, with degenerative diseases, wound healing, and other applications stimulating progress.

Our work shows you what products and organisations hold greatest potential. See profiles of 18 leading companies, including these:
• Advanced Cell Technology
• Anterogen
• Genzyme
• Mesoblast
• NuVasive
• Organogenesis
• Osiris Therapeutics
• Shire Regenerative Medicine
• TiGenix
• UniQure
• Alphatec Spine
• Avita Medical

In general, a company profile gives you the following information
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations.
• Analysis of current clinical trial activity
• Insight into pipeline products in development

Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will improved regulatory processes have? Advances in stem cell science and an evolving patent landscape will change the industry.

How the Translational Regenerative Medicine: Market Prospects 2014-2024 report helps you

In summary, our 240 page report gives you the following knowledge:
• Revenues forecasts to 2024 for the overall world regenerative medicine market and 3 submarkets - discover that industry's prospects, finding promising places for investments and revenues
• Potential revenues of leading regenerative medicine products and portfolios to 2024
• Assessment of 18 leading companies, and others, discovering activities and outlooks
• Market forecasting to 2024 for leading regions - US, Europe, and Asia-Pacific
• Review of the late-stage product pipeline by market segment and therapeutic area
• View opinions from our survey, seeing interviews with authorities
• Investigation of competition and opportunities influencing sales
• Discussion of what stimulates and restrains the industry and market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.
1. Executive Summary

1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods
1.4 Glossary of Terms in this Report

2. Introduction to Translational Regenerative Medicine

2.1 What is Translational Regenerative Medicine?
2.2 Translational Regenerative Medicine: Market Segmentation
2.2.1 Stem Cell Therapy
2.2.1.1 Classifying Stem Cells by Potency
2.2.1.2 Categories of Stem Cells
2.2.1.3 Autologous versus Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.2.1.4 Stem Cell Therapeutic Applications
2.2.2 Tissue Engineering
2.2.3 Gene Therapy
2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
2.3 Other Areas of Regenerative Medicine
2.3.1 Small Molecules and Proteins - Enhancing Regenerative Medicine
2.3.2 Cosmetic Applications of Regenerative Medicine
2.4 Regulation of Regenerative Medicine
2.4.1 Regulation of Regenerative Medicine Products in Europe
2.4.2 Regulation of Regenerative Medicine Products in the US
2.5 Phases of Clinical Trials
2.6 Scope of this Report
2.6.1 Products Excluded from this Report

3. Regenerative Medicine: World Market 2014-2024

3.1 The World Regenerative Medicine Market in 2012 and 2013
3.2 Leading Regenerative Medicine Products
3.3 Leading Companies in the Regenerative Medicine Market
3.4 World Regenerative Medicine Market: Sales Forecast 2014-2024
3.4.1 Regenerative Medicine Market Segments: Sales Forecasts 2014-2024
3.4.2 Regenerative Medicine: CAGRs by Segment 2014-2024
3.4.3 Changing Market Shares by Segment 2014-2024
3.5 Stem Cell Therapies Lead the Regenerative Medicine Market
3.5.1 Stem Cells Therapy Market: Drivers and Restraints 2014-2024
3.6 Tissue Engineered Products Will Continue Strong Growth
3.6.1 Tissue Engineered Products Market: Drivers and Restraints 2014-2024
3.7 Gene Therapies Show High Growth Potential
3.7.1 Gene Therapy Market: Drivers and Restraints 2014-2024

4. Leading National Markets 2014-2024

4.1 Regional Breakdown of the World Regenerative Medicine Market
4.2 World Regenerative Medicine Market: Regional Forecast 2014-2024
4.2.1 Regenerative Medicine: CAGRs by Regional Market 2014-2024
4.2.2 How Will Regional Market Shares Change to 2024?
4.3 The US Regenerative Medicine Market 2014-2024
4.3.1 US Regenerative Medicine Market: Drivers and Restraints
4.3.2 US Market Overview: The Leading Regenerative Medicine Market
4.3.2.1 Regulation of Regenerative Medicine in the US
4.3.2.2 Embryonic Stem Cell Research Remains Controversial
4.3.2.3 An End to Patents on Human Genes?
4.4 The European Regenerative Medicine Market 2014-2024
4.4.1 European Regenerative Medicine Market: Drivers and Restraints
4.4.2 European Market Overview: A Strong Science Base
4.4.2.1 On the Brink of a Unitary European Patent System
4.4.2.2 Regulation of Regenerative Medicine in Europe
4.4.2.3 European REMEDiE Project
4.4.2.4 A UK Perspective on the Regenerative Medicine Market
4.4.2.5 Developments in the Russian Regenerative Medicine Market
4.5 The Asia-Pacific Regenerative Medicine Market 2014-2024
4.5.1 Asia-Pacific Regenerative Medicine Market: Drivers and Restraints
4.5.2 Asia-Pacific Market Overview: Towards Rapid Commercialisation
4.5.2.1 Japan: Transforming the Regulatory Landscape
4.5.2.2 China: Encouraging Stem Cell R&D
4.5.2.3 India: An Emerging RM Industry
4.5.2.4 South Korea: First to Approve Stem Cell Treatments
4.5.2.5 Australia: Encouraging Translational Regenerative Medicine
4.6 The Regenerative Medicine Market in the Rest of the World 2014-2024
4.6.1 Brazil - An Emerging Market in South America

5. Leading Companies in the Regenerative Medicine Market

5.1 Aastrom Biosciences: Developing Cardiovascular Stem Cell Therapies
5.1.1 Aastrom Biosciences: Clinical Trials
5.1.2 Aastrom Biosciences: Products in Development
5.1.2.1 Ixmyelocel-T: Autologous Mesenchymal Stem Cell Therapy
5.2 Advanced Cell Technology: Stem Cells for Eye Diseases
5.2.1 Advanced Cell Technology: Clinical Trials
5.2.2 Advanced Cell Technology: Products in Development
5.2.2.1 Retinal Pigment Epithelial Cell Therapy
5.2.2.2 iPSC-derived Platelets
5.2.2.3 Hemangioblast Program
5.2.2.4 Mesenchymal Stem Cell Program
5.2.2.5 Other Products
5.3 Alphatec Spine: Bone Allgrafts
5.3.1 Alphatec Spine: Clinical Trials
5.3.2 Alphatec Spine: Products in Development
5.4 Anterogen: South Korean Stem Cell Company
5.4.1 Anterogen: Clinical Trials
5.4.2 Anterogen: Products in Development
5.5 Athersys: Developing Allogeneic Progenitor Cell Therapy
5.5.1 Athersys: Clinical Trials
5.5.2 Athersys: Products in Development
5.5.2.1 MultiStem: Allogeneic Multipotent Adult Progenitor Cells
5.5.2.2 Serotonin Receptor Agonists
5.6 Avita Medical: Spray-On Skin Cell Therapy
5.6.1 Avita Medical: Clinical Trials
5.7 AxoGen: Nerve Regeneration Products
5.7.1 AxoGen: Clinical Trials
5.7.2 AxoGen: Products in Development
5.8 Genzyme (acquired by Sanofi): A Leader in Regenerative Medicine
5.8.1 Genzyme: Clinical Trials
5.8.2 Genzyme: Products in Development
5.9 Medipost: Cartilage Repair with Cartistem
5.9.1 Medipost: Clinical Trials
5.9.2 Medipost: Products in Development
5.10 Mesoblast: An Australian RM Leader
5.10.1 Mesoblast : Clinical Trials
5.10.2 Mesoblast: Products in Development
5.10.2.1 NeoFuse
5.10.2.2 Prochymal
5.10.2.3 Chondrogen
5.10.2.4 Mesenchymal Precursor Cells in Congestive Heart Failure
5.10.2.5 Other Pipeline Products
5.11 NuVasive: Spinal Surgery Bone Allografts
5.11.1 NuVasive: Clinical Trials
5.11.2 NuVasive: Products in Development
5.12 Organogenesis: a Tissue Engineering Pioneer
5.12.1 Organogenesis: Clinical Trials
5.12.2 Organogenesis: Products in Development
5.13 Osiris Therapeutics: a Leading Stem Cell Company
5.13.1 Osiris Therapeutics: Clinical Trials
5.13.2 Osiris Therapeutics: Products in Development
5.14 Pharmicell: South Korean Stem Cell Leader
5.14.1 Pharmicell: Clinical Trials
5.14.2 Pharmicell: Products in Development
5.15 Regenerys: Manufacturing Skin Substitutes
5.15.1 Regenerys: Clinical Trials
5.15.2 Regenerys: Products in Development
5.16 Shire Regenerative Medicine: Entering the RM Market
5.16.1 Shire: Clinical Trials
5.16.2 Shire: Products in Development
5.16.2.1 Vascugel
5.17 TiGenix: European Cell Therapy Leader
5.17.1 TiGenix: Clinical Trials
5.17.2 TiGenix: Products in Development
5.18 UniQure: First Gene Therapy Approved in Europe
5.18.1 UniQure: Clinical Trials
5.18.2 UniQure: Products in Development

6. Stem Cell Therapy: Leading Applications 2014-2024

6.1 Stem Cell Therapy: Currently Available Therapies
6.1.1 Haematopoietic Stem Cell Transplantation (HSCT)
6.1.2 Stem Cell Orthobiologics
6.1.2.1 Osteocel Plus (NuVasive): Sales Forecast 2014-2024
6.1.2.2 Trinity ELITE and Trinity Evolution (Orthofix): Sales Forecast 2014-2024
6.1.2.3 LiquidGen (Skye Orthobiologics)
6.1.2.4 AlloStem (AlloSource)
6.1.2.5 PureGen (AlphaTec Spine)
6.1.3 Other Approved Stem Cell Therapy Products
6.1.3.1 Prochymal (remestemcel-L, Osiris Therapeutics/Mesoblast): Sales Forecast 2014-2024
6.1.3.2 Hearticellgram-AMI (Pharmicell)
6.1.3.3 Cupistem (Anterogen)
6.1.3.4 Cartistem (Medipost)
6.2 Stem Cell Therapy Pipeline to 2024
6.2.1 Late-Stage Pipeline for Stem Cell Therapies
6.2.1.1 StemEx (carlecortemcel-L, Gamida Cell)
6.2.1.2 Mesenchymal Precursor Cell Therapies (Mesoblast)
6.2.1.3 Adult Autologous CD34+ Cells (Baxter)
6.2.1.4 MyoCell (Bioheart)
6.2.1.5 Cx601 (TiGenix)
6.2.1.6 Adipose-Derived Stem Cells (Cytori Therapeutics)
6.2.1.7 Stempeucel (Stempeutics Research)
6.2.1.8 C-Cure (Cardio3 BioSciences)
6.2.1.9 Other Late-Stage Stem Cell Therapies
6.2.2 Diabetes and Stem Cell Therapy
6.2.2.1 Mesenchymal Precursor Cells (Mesoblast)
6.2.2.2 VC-01 (ViaCyte)
6.2.3 Cardiovascular Disease and Stem Cell Therapy
6.2.3.1 Endometrial Regenerative Cells (Medistem)
6.2.3.2 AMR-001 (NeoStem)
6.2.3.3 CAP-1002 (Capricor)
6.2.4 Stem Cell Therapy in Cancer
6.2.4.1 CLT-008 (Cellerant Therapeutics)
6.2.4.2 OncoCyte/BioTime - Targeting Cancer with Gene and Stem Cell Therapy
6.2.5 Stem Cell Therapy for CNS Conditions
6.2.5.1 NurOwn (BrainStorm Cell Therapeutics)
6.2.5.2 NSI-566 (Neuralstem)
6.2.5.3 MultiStem (Athersys)
6.2.5.4 PDA-001 (cenplacel-L, Celgene)
6.2.5.5 ALD-401 (Cytomedix)
6.2.5.6 ReN001 (ReNeuron)
6.2.6 Stem Cell Therapy for Eye Diseases
6.2.6.1 MA09-hRPE (Advanced Cell Technology)
6.2.6.2 HuCNS-SC (StemCells, Inc.)
6.2.6.3 EC200 (EyeCyte)
6.2.6.4 Pfizer's Collaboration with The London Project to Cure Blindness

7. Tissue Engineering: Leading Applications 2014-2024

7.1 Tissue Engineering: Currently Available Therapies
7.1.1 Tissue Engineering for Wound Repair
7.1.1.1 Apligraf (Organogenesis): Sales Forecast 2014-2024
7.1.1.2 BioDfence and BioDfactor (BioD)
7.1.1.3 CureXcell (MacroCure)
7.1.1.4 Dermagraft (Shire): Sales Forecast 2014-2024
7.1.1.5 Epicel (Sanofi)
7.1.1.6 Grafix (Osiris Therapeutics)
7.1.1.7 MySkin and CyroSkin (Regenerys)
7.1.1.8 ReCell (Avita Medical): Sales Forecast 2014-2024
7.1.2 Tissue Engineering for Cartilage Repair: Autologous Chondrocyte Implantation
7.1.2.1 Carticel (Sanofi)
7.1.2.2 ChondroCelect (TiGenix)
7.1.2.3 DeNovo NT (Zimmer)
7.1.2.4 MACI (Sanofi)
7.1.3 Other Available Tissue Engineering Therapies
7.1.3.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)
7.1.3.2 Gintuit (Organogenesis)
7.1.3.3 LAVIV (azficel-T, Fibrocell Science)
7.1.3.4 Acellular Tissue Engineering Products
7.2 Tissue Engineering Pipeline to 2024
7.2.1 Autologous Chondrocyte Implantation Pipeline
7.2.2 Tissue Engineering for Skin
7.2.3 Tissue Engineering for Liver Disease
7.2.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)
7.2.4 Tissue Engineering for Cardiovascular Disease
7.2.5 Tissue Engineering for Eye Diseases
7.2.6 Prospects for Organ Transplantation

8. Gene Therapy: Leading Applications 2014-2024

8.1 Gene Therapy: Currently Available Therapies
8.1.1 Gendicine (Benda Pharmaceutical)
8.1.2 Oncorine (Shanghai Sunway Biotech)
8.1.3 Neovasculgen (Human Stem Cells Institute)
8.1.4 Neovasculgen (HSCI): Sales Forecast 2014-2024
8.1.5 Glybera (UniQure)
8.2 Withdrawn From Sale: Rexin-G (Epeius Biotechnologies)
8.3 Gene Therapy Pipeline to 2024
8.3.1 Late-Stage Gene Therapy Pipeline
8.3.1.1 Collategene (beperminogene perplasmid, AnGes MG/Vical)
8.3.1.2 ProstAtak (AdV-tk, Advantagene)
8.3.1.3 Trinam (taberminogene vadenovec, Ark Therapeutics)
8.3.1.4 TVEC (talimogene laherparepvec, Amgen)
8.3.1.5 AAV2-hRPE65v2 (Spark Therapeutics)
8.3.1.6 CG0070 (Cold Genesys)
8.3.2 Gene Therapy for Diabetes
8.3.3 Gene Therapy for Cancer
8.3.4 Gene Therapy for Neurological Diseases
8.3.5 Gene Therapy for Haemophilia B

9. Qualitative Analysis of the Regenerative Medicine Market 2014-2024

9.1 SWOT Analysis of the Regenerative Medicine Market
9.2 Strengths
9.2.1 Incremental Progress in Research
9.2.2 Regulatory Frameworks Improving
9.2.3 An Established Route to Market
9.2.4 Strong Support from National Governments
9.3 Weaknesses
9.3.1 Lack of Venture Capital
9.3.2 High Costs of RM Therapies
9.3.3 Commercialisation Requires New Business Models
9.3.4 Lack of Standardisation
9.4 Opportunities
9.4.1 Disruptive RM Therapies Can Create New Markets
9.4.2 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
9.4.3 Increasing Burden of Chronic Disease
9.4.4 Medical Tourism Can Drive the Market
9.5 Threats
9.5.1 Restraints on Reimbursement
9.5.2 Difficulty Establishing an Evidence Base
9.5.3 Ethical Concerns Limiting R&D
9.5.4 Progress May be Slow
9.6 Porter's Five Forces Analysis of the Regenerative Medicine Market
9.6.1 Rivalry Among Competitors [Medium]
9.6.2 Threat of New Entrants [Medium]
9.6.3 Power of Suppliers [Low]
9.6.4 Power of Buyers [Low]
9.6.5 Threat of Substitutes [High]

10. Research Interviews

10.1 Interview with Dr Alan Trounson, President, California Institute for Regenerative Medicine (CIRM)
10.1.1 Improved Funding in the Stem Cells Field
10.1.2 MSCs: Major Potential or Merely a Placeholder?
10.1.3 CIRM Investment Strategies
10.1.4 The Changing Regulatory Environment Worldwide
10.1.5 Key Trends for the Next Five to Ten Years
10.2 Interview with Professor Francois Berthiaume, Associate Professor of Biomedical Engineering, Rutgers University, New Jersey
10.2.1 On the Regenerative Medicine Market
10.2.2 On the Future of Stem Cell Therapies
10.2.3 Challenges in the Tissue Engineering Market
10.2.4 Thoughts on Future Developments
10.3 Interview with Dr William Dolphin, CEO, Avita Medical, UK
10.3.1 Future Prospects for the Regenerative Medicine Market
10.3.2 Is Regenerative Medicine Ready For Commercialisation?
10.3.3 On Emerging Regenerative Medicine Markets
10.3.4 Future Therapeutic Areas
10.3.5 Barriers to Developing Regenerative Medicine?
10.3.6 Thoughts on Future Developments

11. Conclusions

11.1 The World Regenerative Medicine Market in 2012 and 2013
11.1.1 Current Leading Regenerative Medicine Segments
11.1.2 Leading Regenerative Medicine Products
11.1.3 Leading Regenerative Medicine Companies
11.1.4 Leading Regional Markets
11.2 World Regenerative Medicine Market Forecast 2014-2024
11.3 Regenerative Medicine Late-Stage Pipeline
11.4 The Future of the Regenerative Medicine Market?

List of Tables

Table 1.1 Currency Exchange Rates, 2012
Table 2.1 European Union Definitions of Regenerative Medicine Products, 2013
Table 2.2 Potency and Source of Stem Cells, 2013
Table 2.3 Germ Layers and Their Associated Cells, Tissues and Organs, 2013
Table 2.4 Stem Cell Categories, 2013
Table 2.5 Stem Cell Donor Terminology, 2013
Table 2.6 Clinical Trial Phases
Table 3.1 World Regenerative Medicine Market: Revenues ($m) and Market Shares (%) by Segment, 2012
Table 3.2 Leading Regenerative Medicine Products: Revenues ($m), 2012
Table 3.3 Leading Companies in the Regenerative Medicine Market: Leading Products and Net Revenues ($m), 2012
Table 3.4 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 3.5 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2012-2018
Table 3.6 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2018-2024
Table 3.7 World Regenerative Medicine Market: CAGR (%) by Segment, 2012-2018, 2018-2024 and 2012-2024
Table 3.8 Market Shares (%) of the Regenerative Medicine Market by Segment, 2012, 2018 and 2024
Table 3.9 Stem Cell Market: Revenues ($m) and Market Shares (%) by Subsegment, 2012
Table 3.10 Stem Cell Therapy Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 3.11 Tissue Engineered Products Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 3.12 Gene Therapy Market: Commercial-Stage Products, 2013
Table 3.13 Gene Therapy Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 3.14 Gene Therapy Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Product, 2012-2024
Table 4.1 World Regenerative Medicine Market: Revenues ($m) and Market Shares (%) by Region, 2012
Table 4.2 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2012-2018
Table 4.3 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2018-2024
Table 4.4 World Regenerative Medicine Market: CAGR (%) by Region, 2012-2018, 2018-2024 and 2012-2024
Table 4.5 Market Shares (%) of the Regenerative Medicine Market by Region in 2012, 2018 and 2024
Table 4.6 US Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.7 European Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.8 Asia-Pacific Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 4.9 Rest of the World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 5.1 Aastrom Biosciences: Regenerative Medicine Clinical Trials, 2013
Table 5.2 Advanced Cell Technology: Regenerative Medicine Clinical Trials, 2013
Table 5.3 AlphaTec Spine: Regenerative Medicine Clinical Trials, 2013
Table 5.4 Anterogen: Regenerative Medicine Clinical Trials, 2013
Table 5.5 Athersys: Regenerative Medicine Clinical Trials, 2013
Table 5.6 Avita Medical: Regenerative Medicine Clinical Trials, 2013
Table 5.7 AxoGen: Regenerative Medicine Clinical Trials, 2013
Table 5.8 Genzyme: Products in the US Market, 2013
Table 5.9 Genzyme: Regenerative Medicine Clinical Trials, 2013
Table 5.10 Medipost: Regenerative Medicine Clinical Trials, 2013
Table 5.11 Mesoblast: Regenerative Medicine Clinical Trials, 2013
Table 5.12 NuVasive: Regenerative Medicine Clinical Trials, 2013
Table 5.13 Organogenesis: Regenerative Medicine Clinical Trials, 2013
Table 5.14 Osiris Therapeutics: Regenerative Medicine Clinical Trials, 2013
Table 5.15 Pharmicell: Regenerative Medicine Clinical Trials, 2013
Table 5.16 Regenerys: Regenerative Medicine Clinical Trials, 2013
Table 5.17 Shire: Regenerative Medicine Clinical Trials, 2013
Table 5.18 TiGenix: Regenerative Medicine Clinical Trials, 2013
Table 5.19 UniQure: Regenerative Medicine Clinical Trials, 2013
Table 6.1 Selected Currently Available Stem Cell Products, 2013
Table 6.2 FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2013
Table 6.3 Stages of Osteogenesis, 2013
Table 6.4 NuVasive: Osteocel Plus Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024
Table 6.5 Orthofix: Trinity ELITE Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024
Table 6.6 Mesoblast: Prochymal Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024
Table 6.7 Stem Cell Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2013
Table 7.1 Selected Currently Available Tissue Engineering Products, 2013
Table 7.2 Organogenesis: Apligraf Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024
Table 7.3 Shire: Dermagraft Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024
Table 7.4 Avita Medical: ReCell Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024
Table 7.5 Vital Therapies: Extracorporeal Bio-Artificial Liver Therapy Clinical Trials, 2013
Table 8.1 Currently Available Gene Therapies, 2013
Table 8.2 Benda Pharmaceutical: Gendicine Clinical Trials, 2013
Table 8.3 Human Stem Cells Institute: Neovasculgen Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024
Table 8.4 UniQure: Glybera Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024
Table 8.5 Gene Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2013
Table 8.6 Advantagene: Gene Therapy Clinical Trials, 2013
Table 8.7 Amgen: TVEC Clinical Trials, 2013
Table 8.8 Spark Therapeutics: AAV2-hRPE65v2 Clinical Trials, 2013
Table 9.1 SWOT Analysis of the Regenerative Medicine Market, 2014-2024
Table 9.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2013-2024

List of Figures

Figure 2.1 Brief History of Stem Cell Research, 1900-2000
Figure 2.2 Brief History of Tissue Engineering, 1900-2013
Figure 2.3 Examples of FDA-Approved Tissue Engineered Products
Figure 2.4 Brief History of Gene Therapy, 1970-2013
Figure 3.1 World Regenerative Medicine Market: Market Shares (%) by Segment, 2012
Figure 3.2 Leading Regenerative Medicine Products: Market Shares (%), 2012
Figure 3.3 World Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024
Figure 3.4 World Regenerative Medicine Market Forecast: Revenues ($m) by Segment, 2012-2024
Figure 3.5 World Regenerative Medicine Market Forecast: CAGR (%) by Segment, 2012-2018
Figure 3.6 World Regenerative Medicine Market Forecast: CAGR (%) by Segment, 2018-2024
Figure 3.7 World Regenerative Medicine Market Forecast: CAGR (%) by Segment, 2012-2024
Figure 3.8 World Regenerative Medicine Market: Market Shares (%) by Segment, 2018
Figure 3.9 World Regenerative Medicine Market: Market Shares (%) by Segment, 2024
Figure 3.10 Stem Cell Market: Market Shares (%) by Subsegment, 2012
Figure 3.11 Stem Cell Therapy Market Forecast: Revenues ($m), 2012-2024
Figure 3.12 Stem Cell Therapy Market: Drivers and Restraints, 2014-2024
Figure 3.13 Tissue Engineered Products Market Forecast: Revenues ($m), 2012-2024
Figure 3.14 Tissue Engineered Products Market: Drivers and Restraints, 2014-2024
Figure 3.15 Gene Therapy Market Forecast: Revenues ($m), 2012-2024
Figure 3.16 Gene Therapy Market: Market Shares (%) by Product, 2012
Figure 3.17 Gene Therapy Market: Market Shares (%) by Product, 2018
Figure 3.18 Gene Therapy Market: Market Shares (%) by Product, 2024
Figure 3.19 Gene Therapy Market: Drivers and Restraints, 2014-2024
Figure 4.1 World Regenerative Medicine Market: Revenues ($m) by Region, 2012
Figure 4.2 World Regenerative Medicine Market: Market Shares (%) by Region, 2012
Figure 4.3 World Regenerative Medicine Market Forecast: Revenues ($m) by Region, 2012-2024
Figure 4.4 World Regenerative Medicine Market Forecast: CAGR (%) by Region, 2012-2018
Figure 4.5 World Regenerative Medicine Market Forecast: CAGR (%) by Region, 2018-2024
Figure 4.6 World Regenerative Medicine Market Forecast: CAGR (%) by Region, 2012-2024
Figure 4.7 World Regenerative Medicine Market: Market Shares (%) by Region, 2018
Figure 4.8 World Regenerative Medicine Market: Market Shares (%) by Region, 2024
Figure 4.9 US Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024
Figure 4.10 US Regenerative Medicine Market: Drivers and Restraints, 2014-2024
Figure 4.11 European Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024
Figure 4.12 European Regenerative Medicine Market: Drivers and Restraints, 2014-2024
Figure 4.13 Asia-Pacific Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024
Figure 4.14 Asia-Pacific Regenerative Medicine Market: Drivers and Restraints, 2014-2024
Figure 4.15 Rest of the World Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024
Figure 6.1 NuVasive: Osteocel Plus Revenue Forecast ($m), 2012-2024
Figure 6.2 Orthofix: Trinity ELITE Revenue Forecast ($m), 2012-2024
Figure 6.3 Mesoblast: Prochymal Revenue Forecast ($m), 2012-2024
Figure 7.1 Organogenesis: Apligraf Revenue Forecast ($m), 2012-2024
Figure 7.2 Shire: Dermagraft Revenue Forecast ($m), 2012-2024
Figure 7.3 Avita Medical: ReCell Revenue Forecast ($m), 2012-2024
Figure 8.1 Human Stem Cells Institute: Neovasculgen Revenue Forecast ($m), 2012-2024
Figure 8.2 UniQure: Glybera Revenue Forecast ($m), 2012-2024
Figure 9.1 World 65+ Population Forecast: Size (m), 2013-2024
Figure 9.2 Porter's Five Forces Analysis of the Regenerative Medicine Market, 2014-2024
Figure 11.1 World Regenerative Medicine Market: Revenues ($m) by Segment, 2012
Figure 11.2 World Regenerative Medicine Market: Revenues ($m) by Region, 2012
Figure 11.3 World Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024

Companies Listed

Aastrom Biosciences
Adiposet Ltd (merged into Regenerys)
Advanced BioHealing (acquired by Shire)
Advanced Cell Technology (ACT)
Advanced Tissue Sciences (ATS)
Advantagene
Allosource
AlphaTec Spine
Altrika (acquired by Regenerys)
Amedica
Amgen
Amorcyte (acquired by NeoStem)
Amorepacific Corporation
Amsterdam Molecular Therapeutics (predecessor of UniQure)
AnGes MG
Angioblast Systems (acquired by Mesoblast)
Anika Therapeutics
AnorMED (acquired by Genzyme)
Anterogen (subsidiary of Bukwang Pharm Co Ltd)
Arcarios B.V.
Ark Therapeutics
Arteriocyte
Athersys
Avita Medical
AxoGen
AxoGen Corporation (merged into AxoGen)
Baxter International
Beike Biotechnology
Benda Pharmaceutical
BioD
Bioheart
BioMed Realty Trust, Inc.
BioSante Pharmaceuticals
BioTime
BioTissue
BioVex Group (acquired by Amgen)
Blackstone Medical (acquired by Orthofix)
Bluebird Bio
BrainStorm Cell Therapeutics Inc.
Bukwang Pharm Co Ltd
California Stem Cell
Capricor
Cardio3 BioSciences
CDI
Celgene
Cell Targeting
CellCoTec
Cellerant Therapeutics
Cellerix (merged into TiGenix)
Cephalon
Ceregene
CHA Biotech
Chiesi Farmaceutici SpA
Cipla
Clinical Cell Culture (C3) (merged into Avita Medical)
Clinimmune Labs
co.don
Cold Genesys
Cook Biotech Incorporated
CryoCenter Saint-Petersburg
CytoMedix
Cytori Therapeutics
Daiichi Sankyo
Dendreon
DePuy Mitek (subsidiary of Johnson & Johnson)
Epeius Biotechnologies
EyeCyte
Fibrocell Science
Gamida Cell Ltd
Gemabank
Genpharm
Genzyme (subsidiary of Sanofi)
Geron
Histogenics
Humacyte
Human Stem Cells Institute
Insulete Inc
Introgen Therapeutics
ISTO Technologies
Japan Tissue Engineering Co. (J-TEC)
JCR Pharmaceuticals Co.
Johnson & Johnson
Kinetic Concepts Inc. (merging into KCI)
LecTec Corporation (merged into AxoGen)
LifeCell (merging into KCI)
Lincoln Park Capital
Lonza
MacroCure
Medipost
Medistem (formerly Medistem Laboratories)
Medtronic
Mesoblast
Mitsubishi Tanabe
Musculoskeletal Transplant Foundation (MTF)
Myriad Genetics
Mytogen
National Marrow Donor Program (NMDP) (US)
NeoStem
Neuralstem
New York Blood Center
Nippon Zoki Pharmaceutical
NuVasive
OncoCyte (subsidiary of BioTime)
Organogenesis
Organovo
Oristem
Orthofix
Orthomimetics Ltd (acquired by TiGenix)
Osiris Theraeutics
Oxford BioMedica
Parcell Laboratories
Pervasis Therapeutics (acquired by Shire)
Pfizer
Pharmacells
Pharmicell (formerly FCB-Pharmicell)
Progenitor Cell Therapy (part of NeoStem)
Protek Group
Regenerys
Reliance Life Sciences
ReNeuron
Reprobank
Roslin Cellab
RTI Surgical
Rusnano
Sangamo
Sanofi
Shanghai Qisheng
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
Shire
Shire Regenerative Medicine (subsidiary of Shire)
Skye Orthobiologics
Sotex PharmFirm (subsidiary of Protek Group)
Spark Therapeutics
StemCells, Inc.
Stempeutics Research
Stratatech Corporation
Systagenix (merging into KCI)
TCA Cellular Therapy
Tengion
Teva Pharmaceutical Industries (Teva)
TiGenix
UniQure
University of Colorado Cord Blood Bank
ViaCyte (formerly NovoCell)
Vical
Vindon Scientific
Visiomed Group (merged into Avita Medical)
Vital Therapies, Inc.
WKD Holding Oy
Xcellerex
Xenetic Biosciences
Zentrales Knochenmarkspender-Register Deutschland (German National Registry of Blood Stem Cell Donors) (ZKRD)
Zimmer

Other Organisations Mentioned in This Report

Arthritis Research UK
Associazione Infermieristica per lo Studio delle Lesioni Cutanee (Nursing Association for the Study of Cutaneous Wounds) (AISLeC) (Italy)
Australian Regenerative Medicine Institute
Australian Research Council
Beijing Cancer Hospital
Boston University
British Heart Foundation
California Institute of Regenerative Medicine (CIRM)
Cambridge Stem Cell Biology Institute.
Care Quality Commission (CQC) (UK)
Catalan Institution for Research and Advanced Studies
Cha General Hospital (Seoul, South Korea)
Children's Hospital of Philadelphia
China Food and Drug Administration (CFDA, formerly SFDA)
Chinese Academy of Sciences
Department of Biotechnology (India)
Department of Health (UK)
Duke University School of Medicine
European Medicines Agency (EMA)
European Patent Office
Finnish Red Cross Blood Service
Food and Drug Administration of the Philippines
Harvard Medical School
Haute Autorité de santé (HAS) (French National Authority for Health)
Health Canada
Heriot-Watt University
Human Fertilisation and Embryology Authorityy (HFEA) (UK)
Institute for Regenerative Medicine, Wake Forest University Baptist Medical Center
Institute of Biomedical Research and Innovation Hospital (Kobe, Japan)
International Society for Stem Cell Research
Internet Archive
Japan Patent Office
Japanese Society for Regenerative Medicine
Karolinska Institute
King Fahad Medical City (Saudi Arabia)
LifeSouth Community Blood Centers
London Project to Cure Blindness
Mayo Clinic
Medical Research Council (UK)
Medicines and Healthcare products Regulatory Agency (MHRA) (UK)
Ministry of Economy, Trade and Industry (METI) (Japan)
Ministry of Food and Drug Safety (MFDS, formerly KFDA) (South Korea)
Ministry of Health (China)
Ministry of Health, Labour and Welfare (MHLW) (Japan)
Ministry of Science and Technology (China)
Monash University
Moorfields Eye Hospital
National Health and Medical Research Council (Australia)
National Institutes of Health (US)
National Tissue Engineering Center (NTEC) (China)
Northeast ALS consortium
Pharmaceuticals and Medical Devices Agency (PMDA) (Japan)
Riken Center for Developmental Biology
Russian Ministry of Healthcare and Social Development
Rutgers University
Saudi Food and Drug Authority
Scottish Centre for Regenerative Medicine
Singapore General Hospital
SSM Cardinal Glennon Children's Medical Center
St. Jude's Children Research Hospital
StemGen
SUNY Upstate Medical University
UCL Institute of Ophthalmology
United Nations' Department of Economic and Social Affairs
United States Food and Drug Administration (FDA)
Universitat Autònoma de Barcelona
University College London
University of Edinburgh MRC Centre for Regenerative Medicine
University of Michigan
University of Modena Centre for Regenerative Medicine
University of Wisconsin
US Department of Defense
VA Northern California Health Care System
Weizmann Institute of Science (Rehovot, Israel)
Wellcome Trust
World Health Organization


To order this report: Translational Regenerative Medicine: Market Prospects 2014-2024
http://www.reportlinker.com/p0595030/Translational-Regenerative-Medicine-Market-Prospects-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker